Cargando…

Do neurocognitive impairments explain the differences between brain tumor patients and their proxies when assessing the patient’s IADL?

BACKGROUND: Neurocognitive impairments are common among brain tumor patients, and may impact patients’ awareness of performance in instrumental activities in daily life (IADL). We examined differences between patient- and proxy-reported assessments of the patient’s IADL, and whether the level of (di...

Descripción completa

Detalles Bibliográficos
Autores principales: Oort, Quirien, Dirven, Linda, Sikkes, Sietske A M, Aaronson, Neil, Boele, Florien, Brannan, Christine, Egeter, Jonas, Grant, Robin, Klein, Martin, Lips, Irene M, Narita, Yoshitaka, Sato, Hitomi, Sztankay, Monika, Stockhammer, Günther, Talacchi, Andrea, Uitdehaag, Bernard M J, Reijneveld, Jaap C, Taphoorn, Martin J B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290871/
https://www.ncbi.nlm.nih.gov/pubmed/35855454
http://dx.doi.org/10.1093/nop/npac016
_version_ 1784749010792218624
author Oort, Quirien
Dirven, Linda
Sikkes, Sietske A M
Aaronson, Neil
Boele, Florien
Brannan, Christine
Egeter, Jonas
Grant, Robin
Klein, Martin
Lips, Irene M
Narita, Yoshitaka
Sato, Hitomi
Sztankay, Monika
Stockhammer, Günther
Talacchi, Andrea
Uitdehaag, Bernard M J
Reijneveld, Jaap C
Taphoorn, Martin J B
author_facet Oort, Quirien
Dirven, Linda
Sikkes, Sietske A M
Aaronson, Neil
Boele, Florien
Brannan, Christine
Egeter, Jonas
Grant, Robin
Klein, Martin
Lips, Irene M
Narita, Yoshitaka
Sato, Hitomi
Sztankay, Monika
Stockhammer, Günther
Talacchi, Andrea
Uitdehaag, Bernard M J
Reijneveld, Jaap C
Taphoorn, Martin J B
author_sort Oort, Quirien
collection PubMed
description BACKGROUND: Neurocognitive impairments are common among brain tumor patients, and may impact patients’ awareness of performance in instrumental activities in daily life (IADL). We examined differences between patient- and proxy-reported assessments of the patient’s IADL, and whether the level of (dis)agreement is associated with neurocognitive impairments. METHODS: Brain tumor patients and their proxies completed the phase 3 version of the EORTC IADL-BN32 questionnaire measuring IADL, and patients completed six neurocognitive measures. Patient-proxy difference scores in IADL were compared between patients who were defined as neurocognitively impaired (≥2 neurocognitive measures ≥2.0 standard deviations below healthy controls) and non-neurocognitively impaired. With multinomial logistic regression analyses we examined if neurocognitive variables were independently associated with patient-proxy disagreement in IADL ratings. RESULTS: Patients (n = 81) did not systematically (P < .01) rate IADL outcomes different than their proxies. Proxies did report more problems on 19/32 individual items and all five scales. This effect was more apparent in dyads with a neurocognitively impaired patient (n = 37), compared to dyads with non-neurocognitively impaired patients (n = 44). Multinomial logistic regression analyses showed that several neurocognitive variables (e.g., cognitive flexibility and verbal fluency) were independently associated with disagreement between patients and proxies on different scales. CONCLUSION: Neurocognitive deficits seem to play a role in the discrepancies between brain tumor patients and their proxies assessment of patient’s level of IADL. Although replication of our results is needed, our findings suggests that caution is warranted in interpreting self-reported IADL by patients with neurocognitive impairment, and that such self-reports should be supplemented with proxy ratings.
format Online
Article
Text
id pubmed-9290871
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-92908712022-07-18 Do neurocognitive impairments explain the differences between brain tumor patients and their proxies when assessing the patient’s IADL? Oort, Quirien Dirven, Linda Sikkes, Sietske A M Aaronson, Neil Boele, Florien Brannan, Christine Egeter, Jonas Grant, Robin Klein, Martin Lips, Irene M Narita, Yoshitaka Sato, Hitomi Sztankay, Monika Stockhammer, Günther Talacchi, Andrea Uitdehaag, Bernard M J Reijneveld, Jaap C Taphoorn, Martin J B Neurooncol Pract Original Articles BACKGROUND: Neurocognitive impairments are common among brain tumor patients, and may impact patients’ awareness of performance in instrumental activities in daily life (IADL). We examined differences between patient- and proxy-reported assessments of the patient’s IADL, and whether the level of (dis)agreement is associated with neurocognitive impairments. METHODS: Brain tumor patients and their proxies completed the phase 3 version of the EORTC IADL-BN32 questionnaire measuring IADL, and patients completed six neurocognitive measures. Patient-proxy difference scores in IADL were compared between patients who were defined as neurocognitively impaired (≥2 neurocognitive measures ≥2.0 standard deviations below healthy controls) and non-neurocognitively impaired. With multinomial logistic regression analyses we examined if neurocognitive variables were independently associated with patient-proxy disagreement in IADL ratings. RESULTS: Patients (n = 81) did not systematically (P < .01) rate IADL outcomes different than their proxies. Proxies did report more problems on 19/32 individual items and all five scales. This effect was more apparent in dyads with a neurocognitively impaired patient (n = 37), compared to dyads with non-neurocognitively impaired patients (n = 44). Multinomial logistic regression analyses showed that several neurocognitive variables (e.g., cognitive flexibility and verbal fluency) were independently associated with disagreement between patients and proxies on different scales. CONCLUSION: Neurocognitive deficits seem to play a role in the discrepancies between brain tumor patients and their proxies assessment of patient’s level of IADL. Although replication of our results is needed, our findings suggests that caution is warranted in interpreting self-reported IADL by patients with neurocognitive impairment, and that such self-reports should be supplemented with proxy ratings. Oxford University Press 2022-02-26 /pmc/articles/PMC9290871/ /pubmed/35855454 http://dx.doi.org/10.1093/nop/npac016 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Original Articles
Oort, Quirien
Dirven, Linda
Sikkes, Sietske A M
Aaronson, Neil
Boele, Florien
Brannan, Christine
Egeter, Jonas
Grant, Robin
Klein, Martin
Lips, Irene M
Narita, Yoshitaka
Sato, Hitomi
Sztankay, Monika
Stockhammer, Günther
Talacchi, Andrea
Uitdehaag, Bernard M J
Reijneveld, Jaap C
Taphoorn, Martin J B
Do neurocognitive impairments explain the differences between brain tumor patients and their proxies when assessing the patient’s IADL?
title Do neurocognitive impairments explain the differences between brain tumor patients and their proxies when assessing the patient’s IADL?
title_full Do neurocognitive impairments explain the differences between brain tumor patients and their proxies when assessing the patient’s IADL?
title_fullStr Do neurocognitive impairments explain the differences between brain tumor patients and their proxies when assessing the patient’s IADL?
title_full_unstemmed Do neurocognitive impairments explain the differences between brain tumor patients and their proxies when assessing the patient’s IADL?
title_short Do neurocognitive impairments explain the differences between brain tumor patients and their proxies when assessing the patient’s IADL?
title_sort do neurocognitive impairments explain the differences between brain tumor patients and their proxies when assessing the patient’s iadl?
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290871/
https://www.ncbi.nlm.nih.gov/pubmed/35855454
http://dx.doi.org/10.1093/nop/npac016
work_keys_str_mv AT oortquirien doneurocognitiveimpairmentsexplainthedifferencesbetweenbraintumorpatientsandtheirproxieswhenassessingthepatientsiadl
AT dirvenlinda doneurocognitiveimpairmentsexplainthedifferencesbetweenbraintumorpatientsandtheirproxieswhenassessingthepatientsiadl
AT sikkessietskeam doneurocognitiveimpairmentsexplainthedifferencesbetweenbraintumorpatientsandtheirproxieswhenassessingthepatientsiadl
AT aaronsonneil doneurocognitiveimpairmentsexplainthedifferencesbetweenbraintumorpatientsandtheirproxieswhenassessingthepatientsiadl
AT boeleflorien doneurocognitiveimpairmentsexplainthedifferencesbetweenbraintumorpatientsandtheirproxieswhenassessingthepatientsiadl
AT brannanchristine doneurocognitiveimpairmentsexplainthedifferencesbetweenbraintumorpatientsandtheirproxieswhenassessingthepatientsiadl
AT egeterjonas doneurocognitiveimpairmentsexplainthedifferencesbetweenbraintumorpatientsandtheirproxieswhenassessingthepatientsiadl
AT grantrobin doneurocognitiveimpairmentsexplainthedifferencesbetweenbraintumorpatientsandtheirproxieswhenassessingthepatientsiadl
AT kleinmartin doneurocognitiveimpairmentsexplainthedifferencesbetweenbraintumorpatientsandtheirproxieswhenassessingthepatientsiadl
AT lipsirenem doneurocognitiveimpairmentsexplainthedifferencesbetweenbraintumorpatientsandtheirproxieswhenassessingthepatientsiadl
AT naritayoshitaka doneurocognitiveimpairmentsexplainthedifferencesbetweenbraintumorpatientsandtheirproxieswhenassessingthepatientsiadl
AT satohitomi doneurocognitiveimpairmentsexplainthedifferencesbetweenbraintumorpatientsandtheirproxieswhenassessingthepatientsiadl
AT sztankaymonika doneurocognitiveimpairmentsexplainthedifferencesbetweenbraintumorpatientsandtheirproxieswhenassessingthepatientsiadl
AT stockhammergunther doneurocognitiveimpairmentsexplainthedifferencesbetweenbraintumorpatientsandtheirproxieswhenassessingthepatientsiadl
AT talacchiandrea doneurocognitiveimpairmentsexplainthedifferencesbetweenbraintumorpatientsandtheirproxieswhenassessingthepatientsiadl
AT uitdehaagbernardmj doneurocognitiveimpairmentsexplainthedifferencesbetweenbraintumorpatientsandtheirproxieswhenassessingthepatientsiadl
AT reijneveldjaapc doneurocognitiveimpairmentsexplainthedifferencesbetweenbraintumorpatientsandtheirproxieswhenassessingthepatientsiadl
AT taphoornmartinjb doneurocognitiveimpairmentsexplainthedifferencesbetweenbraintumorpatientsandtheirproxieswhenassessingthepatientsiadl